Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/56243
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJ. Klaewsongkramen_US
dc.contributor.authorP. Thantiworasiten_US
dc.contributor.authorN. Suthumchaien_US
dc.contributor.authorP. Rerknimitren_US
dc.contributor.authorC. Sukasemen_US
dc.contributor.authorP. Tuchindaen_US
dc.contributor.authorL. Chularojanamontrien_US
dc.contributor.authorY. Srinoulpraserten_US
dc.contributor.authorT. Rerkpattanapipaten_US
dc.contributor.authorK. Chanprapaphen_US
dc.contributor.authorW. Disphanuraten_US
dc.contributor.authorP. Chakkavittumrongen_US
dc.contributor.authorN. Tovanabutraen_US
dc.contributor.authorC. Srisuttiyakornen_US
dc.date.accessioned2018-09-05T03:11:22Z-
dc.date.available2018-09-05T03:11:22Z-
dc.date.issued2016-01-01en_US
dc.identifier.issn13652133en_US
dc.identifier.issn00070963en_US
dc.identifier.other2-s2.0-84983655933en_US
dc.identifier.other10.1111/bjd.14701en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84983655933&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/56243-
dc.description.abstract© 2016 British Association of Dermatologists Background: Allopurinol is a frequent cause of severe cutaneous adverse reactions (SCARs), such as drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). The reactions can potentially be fatal. As drug rechallenge in patients with a history of drug-induced SCARs is contraindicated, in vitro testing may have a diagnostic role as a confirmation test. Objectives: To study the diagnostic value of interferon (IFN)-γ enzyme-linked immunospot (ELISpot) assay as a confirmatory test in patients with a history of allopurinol-induced SCARs. Methods: Peripheral blood mononuclear cells (PBMCs) from 24 patients with a history of allopurinol-induced SCAR (13 DRESS, 11 SJS/TEN) and 21 control subjects were incubated with allopurinol or oxypurinol in the presence or absence of antiprogrammed death ligand 1 antibody (anti-PD-L1). The numbers of IFN-γ-releasing cells after stimulation in each group were subsequently measured with ELISpot. Results: The numbers of IFN-γ-releasing cells in allopurinol-allergic subjects were significantly higher than in control subjects when stimulating PBMCs with oxypurinol 100 μg mL−1, especially when adding anti-PD-L1 supplementation. According to the receiver operating characteristic curve results, the optimal discriminatory power of IFN-γ ELISpot in confirming diagnosis of allopurinol-induced SCARs can be obtained using 16 spot-forming cells per 106PBMCs as a cut-off value upon oxypurinol/anti-PD-L1 stimulation (79·2% sensitivity and 95·2% specificity). Conclusions: The measurement of oxypurinol/anti-PD-L1-inducing IFN-γ-releasing cells yields a high diagnostic value in distinguishing between allopurinol-allergic and control subjects. This technique is beneficial in confirming diagnosis of allopurinol-induced SCARs in patients whose reaction develops while taking multiple drugs.en_US
dc.subjectMedicineen_US
dc.titleIn vitro test to confirm diagnosis of allopurinol-induced severe cutaneous adverse reactionsen_US
dc.typeJournalen_US
article.title.sourcetitleBritish Journal of Dermatologyen_US
article.volume175en_US
article.stream.affiliationsChulalongkorn Universityen_US
article.stream.affiliationsKing Chulalongkorn Memorial Hospital, Faculty of Medicine Chulalongkorn Universityen_US
article.stream.affiliationsMahidol Universityen_US
article.stream.affiliationsFaculty of Medicine, Thammasat Universityen_US
article.stream.affiliationsChiang Mai Universityen_US
article.stream.affiliationsPhramongkutklao College of Medicineen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.